Health
Study assesses cardiovascular and renal outcomes for ertugliflozin in patients with type 2 diabetes – News-Medical.Net
A new study led by a cardiologist from Brigham and Women’s Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels
Reviewed by Emily Henderson, B.Sc.Sep 25 2020
A new study led by a cardiologist from Brigham and Women’s Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels.
The Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV) found that the drug had a safety profile similar to that of other SGLT2 inhibitors and did not increase risk of maj…
-
Noosa News23 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
General22 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News19 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
Noosa News21 hours agoMan dies in Gold Coast after rolling trailer pins him to lamp-post